- 041MarketSource · Medical Device Network
SMT adopts Siemens software for device innovation
SMT has implemented Siemens' Teamcenter software to accelerate medical device innovation and manage product lifecycles across the organization. The deployment reflects a vendor's investment in digital infrastructure to improve R&D efficiency and time-to-market for device development.
- 042MarketSource · Medical Device Network
SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics
SOPHiA GENETICS and AstraZeneca announced a partnership to co-develop and launch two companion diagnostics for precision oncology therapies. The collaboration combines SOPHiA's diagnostic software platform with AstraZeneca's oncology drug portfolio, positioning both firms to expand their presence in the companion diagnostics market.
- 043MarketSource · Medical Device Network
KKR to acquire Integer Holdings in $5.7bn all-cash deal
KKR has agreed to acquire Integer Holdings in an all-cash transaction valued at $5.7 billion. Integer Holdings is a supplier of medical devices and components to the healthcare industry, making this a significant consolidation in the medical equipment and supplies vendor landscape.
- 044MarketSource · Medical Device Network
Profusa vies for potential G3 Vision Labs acquisition
Profusa is pursuing a potential acquisition of G3 Vision Labs to expand its diagnostic portfolio with routine chemistry, toxicology, and pathology offerings. The deal would add laboratory diagnostic capabilities to Profusa's existing product lines.
- 045MarketSource · Medical Device Network
CereVasc expands manufacturing with Wilmington facility for eShunt system
CereVasc opened a manufacturing and research facility in Wilmington, Massachusetts to support potential commercialization of its eShunt System, an investigational device for hydrocephalus management. The expansion signals preparation for market entry as the company advances toward regulatory pathways.
- 046MarketSource · Medical Design & Outsourcing
Quasar Medical buys Medres Nitinol Design and Development Center
Quasar Medical, a contract development and manufacturing organization specializing in minimally invasive devices, has acquired Medres' Nitinol Design and Development Center near San Diego. The 10,000-square-foot Carlsbad facility, established in 2024 and expanded in 2025, brings dedicated nitinol engineering talent and manufacturing capabilities to Quasar's operations.
- 047MarketSource · Medical Device Network
Dexcom tweaks full-year outlook after reporting 13% growth in Q2
Dexcom reported 13% revenue growth in Q2 and adjusted its full-year outlook upward following the earnings release on July 30. The company's Nasdaq shares rose over 8% to $81.04 at market open July 31, reflecting investor confidence in the revised guidance.
- 048MarketSource · Medical Device Network
Stryker nets $6.6bn revenue in Q2; highlights resilience following cyberattack
Stryker reported $6.6 billion in Q2 revenue following a March 2026 cyberattack that disrupted global operations. The earnings result demonstrates the company's operational resilience despite the security incident and its recovery efforts.
- 049MarketSource · MedCity News
Why General Catalyst Is Betting $450M on Function Health’s Preventive Care Push
Function Health, a lab-testing and imaging services startup, raised $450 million in growth financing from General Catalyst's Customer Value Fund, eight months after closing a $298 million Series B round. The company plans to use the capital to expand access to its testing and imaging service offerings.
- 050MarketSource · Medical Device Network
Median Technologies and Olea sign partnership for lung cancer device
Median Technologies partnered with Olea Medical to commercialize eyonis LCS, a lung cancer screening software, across the US and European markets. The collaboration expands distribution capabilities for the AI-enabled diagnostic tool designed to support lung nodule analysis in imaging workflows.
- 051MarketSource · Medical Device Network
Baxter’s shares soar by 17% after reporting positive Q2
Baxter International reported a 5% profit increase in Q2 compared to the same period last year, when results were depressed by hurricane damage to a North Carolina manufacturing facility. The earnings announcement drove a 17% surge in the company's stock price.
- 052MarketSource · Medical Device Network
CoreMap raises $37m in Medtronic-led financing round
CoreMap, a privately held medical device company founded in 2016, raised $37 million in a financing round led by Medtronic. The funding nearly doubles the company's total capital raised to date. No additional details on CoreMap's product focus or intended use of proceeds were provided.
- 053MarketSource · Medical Device Network
Trace secures funding from Axogen for nerve imaging technology
Trace Biosciences received strategic funding from Axogen to develop Nerve Trace, a nerve-specific imaging technology. The investment supports advancement of the imaging platform, which targets nerve visualization applications relevant to surgical and diagnostic workflows.
- 054MarketSource · MedCity News
Doctronic Acquires Summer Health to Expand into Pediatric Primary Care
Doctronic acquired Summer Health to expand its AI-powered primary care platform into pediatric care. The deal strengthens Doctronic's digital health offerings and extends its reach into the pediatric primary care segment.
- 055MarketSource · MedCity News
Epic-First Doesn’t Mean Epic-Only: Where Hospitals Are Still Buying from Startups
A survey of 112 health system executives shows Epic's dominance in hospital IT continues to grow, yet startups retain purchasing opportunities by addressing gaps Epic has not filled, delivering measurable ROI, or solving specific clinical or operational problems. The findings suggest a tiered procurement model where health systems prioritize Epic integration but remain open to best-of-breed vendors that complement rather than replace their core platform.
- 056MarketSource · Medical Device Network
Boston Scientific reports positive Q2 results yet opts to trim 2026 outlook
Boston Scientific reported positive second-quarter financial results but reduced its 2026 outlook, citing planned global restructuring efforts. The company's earnings beat expectations, though the forward guidance cut reflects anticipated impacts from the reorganization program on future performance and operations.
- 057MarketSource · MedCity News
Smart Toilet Sensor Startup Is Flush with $10M Funding
Throne Science, a startup developing an AI-powered toilet sensor for monitoring gut health, hydration, and urinary function, closed a $10 million Series A funding round. The company positions the device as an early-warning system for colorectal cancer and other gastrointestinal conditions, addressing a gap in home health monitoring.
- 058MarketSource · Medical Device Network
Boston Scientific expects headcount reductions amid restructuring initiative
Boston Scientific announced a restructuring initiative expected to result in headcount reductions, with total costs estimated between $700 million and $800 million through the end of 2029. The company did not disclose the specific number of positions affected or operational details in the announcement.
- 059MarketSource · Medical Device Network
Xeltis sharpens US market roadmap after €20.5m fundraise
Xeltis raised €20.5 million in funding to refine its US market strategy, following a €47.5 million round completed in December 2025. The Swiss biotech company, which develops bioresorbable scaffolds and regenerative medical devices, is using the capital to accelerate commercialization efforts in North America.
- 060MarketSource · Medical Device Network
Nuwellis’ new CEO on building a strong foundation for sustainable value creation
Mike McCormick assumed the role of CEO at Nuwellis on 30 June, tasked with building on the company's positive Q1 2026 financial results. Nuwellis manufactures renal replacement therapy and fluid management devices for critical care settings. The leadership transition marks a shift in company strategy as McCormick focuses on sustainable value creation and operational foundation-building.
- 061MarketSource · Medical Device Network
Magnendo raises $18m to advance robotic platform
Magnendo closed an $18 million Series A funding round to advance its magnetic robotic navigation platform for neuro-endovascular procedures. The capital will support further development of the technology, which targets minimally invasive vascular interventions in neurology.
- 062MarketSource · Medical Device Network
Medtronic continues assembly of industry’s “broadest” pain therapy portfolio
Medtronic completed its $650 million acquisition of SPR Therapeutics and formally launched ViaVerte at the American Society of Pain Neuromodulation conference on 16 July. The deal expands Medtronic's pain management portfolio, adding peripheral nerve stimulation technology to its existing spinal cord stimulation and neuromodulation offerings.
- 063MarketSource · Medical Device Network
Edwards lifts FY26 growth outlook following steady Q2 performance
Edwards Lifesciences raised its full-year 2026 revenue growth guidance following solid second-quarter results, driven primarily by its transcatheter aortic valve replacement (TAVR) business, which generated $1.26 billion in Q2 revenues. The company's strong TAVR performance underpinned confidence in its revised outlook.
- 064MarketSource · Medical Device Network
bioAffinity and Pictor partner on diagnostics for asthma and COPD
bioAffinity Technologies partnered with Pictor to develop and commercialize diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD). The collaboration combines the companies' capabilities to advance respiratory disease diagnostics, though specific product timelines and technical details were not disclosed.
- 065MarketSource · Medical Design & Outsourcing
Arterex Tecate opens ISO Class 8 clean room facility
Arterex Tecate, a medical device contract manufacturer, opened a 9,000-square-foot ISO Class 8 clean room facility. The expansion increases manufacturing capacity for medical devices and demonstrates the company's investment in quality and regulatory compliance infrastructure.
- 066MarketSource · Medical Device Network
TYBR Health lands $30m to advance orthopaedic hydrogel platform
TYBR Health secured $30 million in funding to expand market access for its B3 GEL orthopaedic hydrogel, which launched in the US in January 2026. The company plans to use the capital primarily to grow distribution and market penetration of the platform.
- 067MarketSource · Medical Design & Outsourcing
Nelipak reports progress on healthcare packaging sustainability
Nelipak Corporation, a healthcare packaging solutions provider, released its 2025 Sustainability Report detailing progress toward long-term sustainability goals and product innovations. The report aligns with the company's stated vision to support sustainable healthcare practices through packaging solutions.
- 068MarketSource · Medical Device Network
Cardinal Health makes acquisition duo worth $360m for home care business advance
Cardinal Health acquired Strive Medical and Adapt Health's diabetes unit in two deals totaling $360 million to expand its home care business. The acquisitions strengthen Cardinal Health's portfolio in at-home medical device and diabetes management services, supporting its stated growth strategy in the home care sector.
- 069MarketSource · Medical Device Network
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal
Tempus AI acquired Personalis for $1.5 billion in an all-stock deal focused on precision oncology. Personalis' minimal residual disease (MRD) testing platform will be integrated into Tempus' oncology portfolio, expanding the combined company's diagnostic and data capabilities in cancer care.
- 070MarketSource · MedCity News
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis
Tempus AI announced a $1.5 billion acquisition of Personalis, a liquid biopsy company specializing in minimal residual disease (MRD) assays that detect remaining cancer cells after treatment. Tempus has served as the commercial partner for Personalis's MRD test since 2023. The deal consolidates two players in the growing cancer diagnostics market.
- 071MarketSource · Medical Design & Outsourcing
Medline to open new distribution facility in California
Medline announced plans to open a 1-million-square-foot distribution facility in Perris, California, expanding its logistics network following a similar buildout in Texas. The facility is intended to increase capacity and operational flexibility for healthcare providers across the state.
- 072MarketSource · Medical Device Network
British Business Bank commits €25m to EQT Life Sciences’ latest fund
The British Business Bank has committed €25 million to EQT Life Sciences' latest fund. The Bank has prior co-investment experience with EQT portfolio companies Phagenesis and Cyted Health, signaling continued backing of the venture capital firm's life-sciences investments.
- 073MarketSource · Medical Device Network
RapidPulse obtains funding for stroke aspiration system
RapidPulse secured $48 million in funding to advance clinical development of its aspiration technology for acute ischemic stroke treatment. The capital will support the company's efforts to move the system through clinical validation and toward market commercialization.
- 074MarketSource · Medical Device Network
GE and Catholic Health enter $500m alliance to expand diagnostics access
GE HealthCare and Catholic Health have formed a 10-year strategic alliance valued at approximately $500 million to expand precision diagnostics, advanced imaging, and AI-supported technology across Catholic Health's Long Island network. The partnership aims to increase access to diagnostic capabilities and modernize imaging infrastructure within the health system.
- 075MarketSource · Medical Device Network
DePuy Synthes expands spine portfolio after Expanding Innovations acquisition
DePuy Synthes acquired Expanding Innovations, gaining access to the company's interbody cage systems for complex spinal surgery. The deal expands DePuy Synthes' spine portfolio.
- 076MarketSource · Medical Device Network
Neko Health raises $700m as US market entry draws closer
Neko Health secured $700 million in funding as the Swedish health-screening company prepares to enter the US market with its first location in New York this year, followed by additional US sites. The funding round supports the company's expansion beyond its existing Scandinavian operations into the American medical-device and diagnostic-screening sector.
- 077MarketSource · Medical Device Network
BIOTRONIK Neuro acquires Soin Neuroscience’s SCS IP portfolio
BIOTRONIK Neuro has acquired an intellectual property portfolio from Soin Neuroscience focused on spinal cord stimulation (SCS) technology. The deal expands BIOTRONIK's neuromodulation capabilities and IP footprint in the SCS market.
- 078MarketSource · MedCity News
Neko Health Secures $700M to Support US Expansion
Neko Health secured $700 million in Series C funding co-led by Lightspeed Venture Partners and O.G. Venture Partners to support US expansion. The round included participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum, and BDT & MSD. Neko operates diagnostic imaging and health-screening services, positioning itself as a vendor in the preventive diagnostics and mobile imaging space.
- 079MarketSource · Medical Device Network
J&J raises FY26 outlook following positive Q2
Johnson & Johnson raised its fiscal 2026 outlook following strong second-quarter results, with MedTech contributing $8.9 billion of the division's $25.3 billion in total Q2 revenues. Growth was driven in part by its cardiovascular portfolio, including the Shockwave IVL lithotripsy system.
- 080MarketSource · Medical Device Network
Women’s health attracted record equity in 2025 as companies share capital
Women's health companies attracted record equity funding in 2025 as investors increased capital allocation to the sector. The surge reflects growing recognition that closing gender health gaps could add over $1 trillion annually to the global economy by 2040, driving venture and growth capital toward female-focused medical device and diagnostic companies.